Please login to the form below

Not currently logged in
Email:
Password:

Indian generic drug firm expands in Russia

India-based Dr Reddy's Laboratories is to acquire the pharmaceutical prescription portfolio of JB Chemicals & Pharmaceuticals in Russia and other CIS nations

India-based Dr Reddy's Laboratories is to acquire the pharmaceutical prescription portfolio of JB Chemicals & Pharmaceuticals in Russia and other CIS nations.

Dr Reddy's will pay $34.85m to acquire the marketing licences for 20 brands, including Metrogyl (metronidazole) for infections and antihistamine Jocet (cetirizine).

Dr Reddy's has also entered into a supply agreement with JB Chemicals for the continued manufacturing and supply of these products associated with the acquired brands.

"Russia is one of our leading markets where we enjoy a strong equity with stakeholders," said Satish Reddy, MD of Dr Reddy's. "This acquisition will help expand our prescription, hospital and OTC portfolio, complement our existing strong basket of products and add to our growth aspirations in the Russia and other CIS region."

Related links

Find out more about the importance of Russia as a market for the pharmaceutical industry at
Russia: The inside story - the first of PMGroup's Country Report Live events.

 

25th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...

Infographics